

Table 1 Overall and adverse event rate of different symptoms of adverse event (AEFI) after DTaP-IPV/Hib vaccination in Guangzhou, China from May 2011 to 2017 (n=376) (Adopted from Li et al., 2020)

| Reporting year and sex | Number of DTaP-IPV/Hib doses distributed | All AEFI reports | | | AEFI reports with serious AEFI | | | | | | | | |
|------------------------|--|------------------|--------|-------|---|--------|-------|------|--------|-------|---|--------|-------|
| | | Sex | | Total | Rate per 100,000 DaP-IPV/ Hib doses distributed | | | Sex | | | Total Rate per 100,000 DaP-IPV/ Hib doses distributed | | |
| | | Male | Female | | Male | Female | Total | Male | Female | Total | Male | Female | Total |
| 2011 | 19598 | 4 | 1 | 5 | 20.4 | 5.1 | 25.5 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 |
| 2012 | 48070 | 12 | 5 | 17 | 25.0 | 10.4 | 35.4 | 1 | 0 | 1 | 2.1 | 0.0 | 2.1 |
| 2013 | 69650 | 23 | 14 | 37 | 33.0 | 20.1 | 53.1 | 0 | 3 | 3 | 0.0 | 4.3 | 4.3 |
| 2014 | 94120 | 39 | 25 | 64 | 41.4 | 26.6 | 68.0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 |
| 2015 | 84280 | 35 | 31 | 66 | 41.5 | 36.8 | 78.3 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 |
| 2016 | 100112 | 76 | 54 | 130 | 75.9 | 53.9 | 129.9 | 2 | 0 | 2 | 2.0 | 0.0 | 2.0 |
| 2017 | 100328 | 39 | 18 | 57 | 38.9 | 17.9 | 56.8 | 2 | 0 | 2 | 2.0 | 0.0 | 2.0 |
| Total | 516158 | 228 | 148 | 376 | 44.2 | 28.7 | 72.8 | 5 | 3 | 8 | 1.0 | 0.6 | 1.5 |

Image caption: This displays the overall and specific adverse event rates of different symptoms of adverse events (AEFI) after DTaP-IPV/Hib vaccination in Guangzhou, China from 2011 to 2017. The data shows that out of 516,000 doses of the vaccine administered, there were 376 reported adverse events (AEFI), with a reporting rate of 72.8 per 100,000 doses. Minor adverse reactions such as fever, redness and swelling at the injection site, and induration were more common, while the rate of severe adverse events was low, accounting for only 2.1%. The incidence of fever after vaccination decreased progressively, from 48.1% after the first dose to 28.0% after the fourth dose, with most cases being Grade I and II fever, and only two cases of severe fever (≥ 38.6 °C) (Adapted from Li et al., 2020)